## 1 Introduction  
Microorganisms, particularly actinomycetes, have long been regarded as one of the most valuable sources of pharmacologically important secondary metabolites, including antiviral, antibacterial, antifungal, and antiparasitic agents; chemotherapeutics; immunomodulatoryulators; and cardiovascular drugs. The extraction of these significant metabolites hastraditionally been achieved through the cultivation of filtrates, yet it has become evident that many compounds remain undiscovered and unexplored [1; 2]. The chemical diversity found in actinomycetes includes a wide range of prominent chemical classes, such as polyketides (PKs), nonribosomal peptides (NRPs), hybrid PK/NRPs, terpen, and ribosomally synthesized and post-translationally modified peptides (RiPPs) [3; 4; 5; 6]. These chemically diverse natural products are produced within highly conserved genetic regions known as biosynthetic gene clusters (BGCs). For decades, natural product discovery has relied primarily on bioactivity-guided isolation approaches. While this method, which uses bioactivity as the main indicator, has demonstrated high success rates, it also comes with several challenges. The isolation of active compounds from complex mixtures is often time-consuming, and non-targeted approaches frequently lead to the rediscovery of known compounds. Therefore, establishing more efficient protocols to reduce the rates of rediscovery and re-isolation during the early stages of drug development from actinomycetes has become a pressing concern [7; 8; 9]. Research into \"rare actinomycetes\" has emerged as a promising approach for uncovering novel drug candidates in nature. The _Lentzea_ genus is a group of rare actinomycetes with significant potential for the exploration of bioactive compounds. Despite their demonstrated capacity to produce medically relevant compounds, the genomic analysis of _Lentzea_ remains underexplored [10; 11; 12]. To date, 58 genomes have been reported in the NCBI genome database. Among these, _Lentzea_ sp. HUAS12 (CP099738.1), _Lentzea_ sp. NBC_00516 (CP107840.1), _Lentzea_ sp. DG15-22 (CP143276.1), and _Lentzea guizhouensis_ DHS C013 (CP016793.1) are the only genomes represented by a single complete contig, while the remaining genomes are draft sequences, some consisting of over 30 contigs, with one even composed of 2241 contigs. The 2020s have ushered in an era of biological revolution driven by advancements in \"omics\" technologies. The convergence of these biological and technological developments has dramatically reduced the cost of DNA sequencing, and unprecedented access to genomic data has made genome mining an indispensable tool in the field of natural product discovery, sparking a renaissance in this area [13; 14; 15]. Genome mining is a technique that analyzes the genomes of actinomycetes to identify biosynthetic gene clusters (BGCs), which enables the prediction of potential natural products that microorganisms can produce. Recent advancements in sequencing technologies, particularly long-read sequencing, have significantly improved the accuracy of genomic analysis in actinomycetes. This has allowed for the discovery of previously hidden BGCs and the efficient exploration of bioactive compounds from actinomycetes [16; 17]. Although chemical structures exhibit remarkable diversity, nature often employs a few mechanisms to generate the same chemical building blocks. By utilizing the genetic signatures of enzymes, researchers can identify new biosynthetic pathways. Once the genetic basis for the production of a molecule is identified, further discoveries become possible. Today, researchers are proficient in analyzing genome sequences to predict whether they BGCs and subsequently target those BGCs for the isolation of related compounds [18; 19; 20]. The word \"Gotjawal\" originates from two Korean terms: \"Got\", which means forest, and \"Jawal\", which refers to thick, bushy vegetation.